Company / PP&E (Net)
Spero Therapeutics, Inc. PP&E (Net) History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$2.0K
FY2023
5-year range
$2.0K / $1.0M
FY2019-FY2023
Trend
-99.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 5 consecutive years, from $3M in FY2018 to $2,000 in FY2023.
Based on SEC 10-K filings.
$2,000 in FY2023 with a 5-year CAGR of -76.7%.
Declined from $1M to $2,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -89.4%
- 5-Year CAGR
- -76.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- Spero Therapeutics, Inc.'s pp&e (net) has declined for 5 consecutive years.
- 5-year CAGR of -76.7%, indicating a declining trend.
- In FY2023, pp&e (net) decreased 99.5% year-over-year.
- Peak pp&e (net) was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $2.0K | -99.5% |
| FY2022 | $368.0K | -64.1% |
| FY2021 | $1.0M | -38.5% |
| FY2020 | $1.7M | -26.6% |
| FY2019 | $2.3M | -21.4% |
| FY2018 | $2.9M | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026